<DOC>
	<DOCNO>NCT00907894</DOCNO>
	<brief_summary>This Phase I , open-label , single-dose study evaluate pharmacokinetics safety LDT600 pediatric adolescent patient chronic hepatitis B infection .</brief_summary>
	<brief_title>Pharmacokinetics Safety Single-Dose Telbivudine Children Adolescents With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>Children adolescents patient HBsAg seropositive Exclusion criterion : Decompensated liver disease ( ChildTurcottePugh ( CTP ) Scoreâ‰¥7 , Class B C ) Prior antiHBV therapy within 30 day study drug dosing . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Chronic hepatitis B ,</keyword>
	<keyword>telbivudine ,</keyword>
	<keyword>pharmacokinetics ,</keyword>
	<keyword>safety ,</keyword>
	<keyword>tolerability ,</keyword>
	<keyword>pediatric</keyword>
</DOC>